Drug Excipient Business Development Reports now Available on Amazon
Drug Patent Watch
FEBRUARY 15, 2024
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch.
Immunovant data show potential for autoimmune disease drug
Bio Pharma Dive
SEPTEMBER 26, 2023
Much anticipated clinical trial data for Immunovant’s experimental FcRn inhibitor could catalyze business development decisions for its parent, Roivant Sciences.
Clinical Trials 
264
264 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Viatris sells off consumer, women’s health drugs in asset sales
Bio Pharma Dive
OCTOBER 2, 2023
The divestments will bring in more than $3 billion as the company works to reduce its debt and plan for future business development.
Sales 156
156 
Customer Success: API and CDMO Business Development
Drug Patent Watch
DECEMBER 3, 2019
Changes in drug markets can create growth opportunities for API manufacturers and CDMOs alike. Whether change comes from generic entry, from new formulations of drugs, or from competition from novel…. The post Customer Success: API and CDMO Business Development appeared first on DrugPatentWatch - Make Better Decisions.
Zerion and Insud to develop Dispersome formulations of drugs
Pharmaceutical Technology
AUGUST 30, 2022
Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.
Development 130
130 
Vodcast: Dr Adriano Flora, The Jackson Laboratory
Drug Discovery World
APRIL 8, 2024
The latest sponsored DDW Sitting Down With vodcast features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory (JAX). He discusses alternatives to non-human primates, the key benefits of this, and what impact will they have on the future of drug development.
New appointments strengthen AI drug discovery software operations
Drug Discovery World
OCTOBER 26, 2022
Optibrium, a software and artificial intelligence (AI) solutions developer for drug discovery, has announced three appointments: Michelle Harrison as Head of Strategic Marketing, Chris Khoury as Associate Director of Business Development, and Imran Ghauri as Business Development Manager. .
Drugs 52
52 
Drug discovery’s latest top-level appointments
Drug Discovery World
SEPTEMBER 5, 2023
The last couple of months have seen a number of high-profile job moves in drug discovery. Stevens has moved from Director of Drug Discovery, where he had been driving Metrion’s scientific strategy to develop new assays. The post Drug discovery’s latest top-level appointments appeared first on Drug Discovery World (DDW).
Drugs 59
59 
Hasten Biopharmaceutic raises $315m for pipeline assets development
Pharmaceutical Technology
APRIL 20, 2023
Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by Singapore-based CBC Group and Abu Dhabi sovereign wealth fund Mubadala Investment, The funding round was supported by additional institutional investors.
Development 246
246 
EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan
The Pharma Data
DECEMBER 13, 2020
.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. He received his B.S.
Drug discovery’s senior appointments for Q4
Drug Discovery World
NOVEMBER 30, 2023
Genomics company Broken String Biosciences has expanded its senior leadership team with the appointments of Vincent Smith as Chief Technology Officer, Jessica Rich as VP Business Development, and Gavin Burns as Vice President of Quality and Operations. Enhanc3D Genomics has appointed Hazel Jones as its new Chief Operating Officer.
Drugs 52
52 
Podcast: China’s opportunities for global drug discovery breakthroughs
Drug Discovery World
SEPTEMBER 22, 2022
This is the latest episode of the free DDW podcast, “China’s opportunities for global drug discovery breakthroughs”. They are called “ Is China entering a new phase for drug discovery? ”, “ Finding drug discovery opportunities in China ” and “ Why biotech in China offers global opportunities ”.
Drugs 52
52 
PTC and Blackstone enter financing partnership of up to $1bn
Pharmaceutical Technology
OCTOBER 28, 2022
PTC will use the network and life sciences capabilities of Blackstone to expand its business development works. PTC Therapeutics chief financial officer Emily Hill said: “This strategic financing will support the acceleration of PTC’s robust and diversified pipeline, business development opportunities and general corporate purposes.
Life Science 130
130 
Orphan drugs and where to launch them: The keys to Europe’s forgotten territories
Pharmaceutical Technology
JULY 14, 2022
The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients.
Drugs 147
147 
This week in drug discovery (8-12 May)
Drug Discovery World
MAY 12, 2023
Inspired by the relaunch of PerkinElmer’s Life Science and Diagnostics business this week as Revvity, my top five news story this week all relate to new drug discovery business developments. The post This week in drug discovery (8-12 May) appeared first on Drug Discovery World (DDW).
Life Science 52
52 
China’s opportunities for global drug discovery breakthroughs
Drug Discovery World
SEPTEMBER 22, 2022
This is the latest episode of the free DDW podcast, “China’s opportunities for global drug discovery breakthroughs”. They are called “ Is China entering a new phase for drug discovery? ”, “ Finding drug discovery opportunities in China ” and “ Why biotech in China offers global opportunities ”.
Drugs 52
52 
Tech Theatre at ELRIG Drug Discovery 2022 highlights sustainability
Drug Discovery World
SEPTEMBER 2, 2022
The Tech Theatre, supported by DDW, at ELRIG Drug Discovery 2022 will feature a series of seminars focused on automation and technology for drug discovery. . Raj Patey, Business Development Director, MyGreenLabs, will be discussing The Sustainable Lab: Building a Global Culture of Sustainability in Science. .
Drugs 52
52 
Drug discovery’s top-level movers and shakers
Drug Discovery World
JUNE 29, 2023
It’s been another busy month for senior appointments in the drug discovery sector. David Favre, Chief Development Officer, SpliceBio Dr Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry.
Drugs 52
52 
Ferrer secures worldwide rights to PSP drug
Drug Discovery World
FEBRUARY 23, 2023
Asceneuron, as a neurodegeneration-focused company, will continue expanding the application of OGA mechanism in other diseases in addition to developing further programs in some of the largest unmet medical need indications in neurology.” Ferrer will now conduct a Phase II clinical study to determine the efficacy and optimal dose range of ASN90.
Drugs 52
52 
Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease
Pharmaceutical Technology
APRIL 3, 2023
Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.
Development 130
130 
SMi’s 3rd Annual AI in Drug Discovery Conference
pharmaphorum
JANUARY 24, 2022
Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare. SMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference , taking place on the 14th and 15th March 2022 in London, UK. Chaired by: Darren Green, Director of Computational Chemistry, GSK.
Drugs 52
52 
China Puts Renewed Focus on Monoclonal Antibodies in COVID-19 Fight
BioSpace
DECEMBER 8, 2021
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, as also working on monoclonal antibody treatments.
Antibody 85
85 
Watch the latest DDW vodcast
Drug Discovery World
APRIL 9, 2024
It features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory (JAX). In this vodcast, he discusses alternatives to non-human primates, the key benefits of this, and what impact will they have on the future of drug development. The latest DDW Sitting Down With sponsored vodcast is now available.
Specialty Treatments in the New Age of Affordability
Drug Channels
AUGUST 18, 2023
Today’s guest post is from Divya Iyer, Vice President of Strategy & Business Development, Pharma Manufacturer Solutions, at GoodRx. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Divya’s insights. This Feed is for personal non-commercial use only.
Taking A Technology-First Approach In Your Affordability Program
Drug Channels
MARCH 10, 2023
Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. Download AssistRx's free 61-page eBook here: Specialty Drug Patient Support Programs: 2022 Progress Report. d/b/a Drug Channels Institute. Read on for Stacey’s insights.
Pharmacy 77
77 
Four ways ChatGPT could impact drug discovery
Drug Discovery World
FEBRUARY 7, 2023
Here, DDW’s Diana Spencer takes a look at the ways ChatGPT and technology like it could change the future of drug discovery and development. So, how could software like this impact drug discovery , an industry that has so far embraced the possibilities of artificial intelligence (AI)?
Drugs 52
52 
Merck snaps up cancer drug from China’s Kelun in $1.4bn deal
pharmaphorum
MAY 18, 2022
Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China’s Sichuan Kelun Pharmaceutical, and is keeping the details close to its chest. A total of $17 million of the upfront payment has already been paid by Merck as part of an earlier collaboration on the drug.
Drugs 57
57 
How Are Biopharma Companies Evaluating Partnerships in the Rare Disease Space?
Camargo
SEPTEMBER 23, 2020
Panel Summary from the World Orphan Drug Congress 2020. Last month, executives from leading international biopharma companies came together at the World Orphan Drug Congress 2020 to discuss how they are evaluating new opportunities in the rare disease space. Thomas Kassberg, Chief Business Officer, Ultragenyx.
Who are the drug discovery industry’s latest movers and shakers?
Drug Discovery World
NOVEMBER 29, 2022
Prior to this, Smith worked at Merck, Sharp and Dohme (MSD), holding positions including Director of Research and Development Analytics. The Native Antigen Company has expanded its management team with the addition of Richard White as Business Development Manager and Pardeep Sharda as Senior Product Manager. .
Gene Therapy 52
52 
WCG Clinical Announces Relaunch of FDAnews as the Premier Source for Drug and Device Insights
WCG Clinical
APRIL 3, 2023
The relaunch will combine the products Drug Industry Daily, Device Daily Bulletin Premium , Drug Daily Bulletin and Device Daily Bulletin into one content destination at FDAnews.com. Contact Will Tuttle, Business Development Representative at wtuttle@fdanews.com or +1 612.216.2948 to receive a custom quote.
Compliance 52
52 
Accelerating time to market through digitalisation
Drug Discovery World
APRIL 18, 2023
Sascha Fischer, Business Development Manager for Automation at Genedata looks at three critical digitalisation components that streamline the journey to market. Username or E-mail Password Remember Me Forgot Password The post Accelerating time to market through digitalisation appeared first on Drug Discovery World (DDW).
Marketing 52
52 
FivepHusion collaborates with Treehill, Syneos for Deflexifol
Pharmaceutical Technology
MAY 29, 2023
FivepHusion has collaborated with Treehill Partners and Syneos Health to strategically progress development and commercialisation of its chemotherapeutic formulation Deflexifol in markets across the globe. Syneos will support the commercialisation and clinical development capabilities of FivepHusion.
Aviko Radiopharmaceuticals plans to advance BNCT for cancer treatment
Pharmaceutical Technology
MAY 11, 2023
Aviko CEO and Deerfield business development vice-president David Greenwald stated: “In spite of improvements in patient outcomes over the past several decades, there is still a significant need for cancer therapies that effectively target cancer cells while leaving healthy tissue unharmed.
Medicine 130
130 
The future's bright for Vetter - from lessons during the pandemic to maintaining a happy team
BioPharma Reporter
NOVEMBER 21, 2023
OSP was delighted to talk to Vetterâs Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.
Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member
The Pharma Data
JANUARY 5, 2021
The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva has been utilizing its unique moss-based platform to produce novel drugs. Ralf Smit as CBO (Chief Business Officer) to its Executive Board.
Drugs 52
52 
Blueprint Medicines announces financing partnerships for $1.25bn
Pharmaceutical Technology
JULY 1, 2022
The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. Ayvakit has received the US Food and Drug Administration (FDA) approval to treat advanced systemic mastocytosis in adults.
Medicine 147
147 
RareMed Expands Concierge Patient Support Services to Complex Conditions
Drug Channels
MAY 4, 2023
Today’s guest post comes from Justin Smerker, VP of Business Development at RareMed Solutions. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Justin introduces us to RareMed Solutions, a patient service provider that caters to patients with complex and rare diseases.
Four Things You Need to Know about Hubs in 2022
Drug Channels
MARCH 11, 2022
Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Stacey analyzes trends in patient support services and reimbursement hubs.
Pharmacy 72
72 
Aqilion and Merck partner to develop TAK1 protein inhibitors
Pharmaceutical Technology
FEBRUARY 16, 2023
Under the deal, Aqilion will receive $10.6m (€10m) in upfront cash payment from Merck and also eligible for up to $1,015m (€950m) in potential development and commercialisation milestone payments, along with tiered royalties on global net sales.
Protein 147
147 
Three Ways to Boost Patient Access to Orphan Drugs—With an Independent Specialty Pharmacy
Drug Channels
SEPTEMBER 18, 2020
Today’s guest post comes from Ela Lourido, Vice President of Business Development at Biologics by Mckesson. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Ela’s insights. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.
Pharmacy 40
40 
Leading pharmaceutical wholesalers
Pharmaceutical Technology
SEPTEMBER 5, 2022
Wholesale distributors are responsible for guaranteeing product quality and preventing the influx of counterfeited drugs. Wholesalers can be either full-line wholesalers, who purchase the complete product line of a company, or specialised companies, which purchase speciality drugs to sell to clinics and hospitals. GDP and GMP advisory.
Packaging 130
130 
CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders
Pharmaceutical Technology
JULY 29, 2022
In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs). The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder. David Bumcrot PhD, CSO, CAMP4 Therapeutics.
RNA 245
245 
New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW
Drug Discovery World
OCTOBER 3, 2022
A series of short seminars focused on automation and technology will be available to visitors at Drug Discovery 2022 which takes place at the ExCel, London 4 and 5 October. will discuss The role of AI and Automation in Personalised Medicine: How can AI Help in the Post- Drug Discovery Process. Fellowship Programme.
Drugs 52
52 
Leading injectables (commercial dose) companies in contract marketing
Pharmaceutical Technology
SEPTEMBER 15, 2022
The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market.
Marketing 130
130 
Let's personalize your content